腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)多克隆抗體
Polyclonal Antibody to Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)
CD253; TNFSF10; APO2L; Apo2-L; TL2; TRAIL; Tumor Necrosis Factor Ligand Superfamily Member 10; Apo-2 Ligand
- 編號PAA139Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來源多抗制備
- 宿主兔
- 效價-
- Ig類型 IgG
- 純化方式抗原特異性親和純化
- 標(biāo)記物無標(biāo)記物
- 免疫原 RPA139Mu01-腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度500μg/mL
- 且適物種Homo sapiens (Human，人)
- 應(yīng)用WB; IHC; ICC; IP.
如果抗體需用于流式細(xì)胞術(shù)，請參見流式抗體。 - 下載 英文說明書 中文說明書
- 規(guī)格 20μl100μl 200μl 1ml 10ml
- 價格 ¥ 583 ¥ 1361 ¥ 1944 ¥ 4860 ¥ 19440
- 欲了解實際交易價格和更多情況，請與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
IHC圖
-
IHC圖
-
IHC圖
-
IHC圖
-
IHC圖
-
AF488 staining on IF;
Sample: MCF7 cell
Primary Ab: 20μg/ml Rabbit Anti-Mouse TRAIL Antibody
Second Ab: 2μg/ml AF488-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb11)
-
Figure. Western Blot; Sample: Recombinant TRAIL, Mouse.
-
Western Blot; Samples: Lane1: 3T3 cell lysate; Lane2: Hepa1-6 cell lysate;
Primary Ab: 0.1μg/ml Rabbit Anti-Mouse TRAIL Antibody
Second Ab: 0.2μg/ml HRP-Linked Caprine Anti-Rabbit IgG Polyclonal Antibody
(Catalog: SAA544Rb19)
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對TRAIL的兔多克隆抗體。在免疫組織化學(xué)染色和免疫印跡實驗中能識別TRAIL。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲存
經(jīng)常使用則4°C保存。-20°C保存不超過兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲，損失率低于5%。
贈品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號 | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA139Mu01 | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA139Mu02 | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA139Mu01 | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)多克隆抗體 | WB; IHC; ICC; IP. |
| PAA139Mu02 | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA139Mu71 | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| SEA139Mu | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| WEA139Mu | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)檢測試劑盒(酶聯(lián)免疫吸附試驗法,寬范圍) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMA139Mu | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
| KSA139Mu01 | 腫瘤壞死因子相關(guān)凋亡誘導(dǎo)配體(TRAIL)檢測試劑盒DIY材料(酶聯(lián)免疫吸附試驗法) | Main materials for "Do It (ELISA Kit) Yourself". |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| PLOS ONE | Intranasal Administration of Recombinant TRAIL Down-Regulates CXCL-1/KC in an Ovalbumin-Induced Airway Inflammation Murine Model [Pubmed:25506835] |
| PLOS ONE | Soluble TRAIL Concentration in Serum Is Elevated in People with Hypercholesterolemia [PubMed: 26633016] |
| Scientific Reports | Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice [pubmed:28507343] |
| Journal of Molecular Medicine | TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer Patients [Pubmed: 31183506] |
| life sciences | Nifuroxazide attenuates experimentally-induced hepatic encephalopathy and the associated hyperammonemia and cJNk/caspase-8/TRAIL activation in rats [Pubmed: 32259601] |
| Int Immunopharmacol | Cardio-protective impact of gabapentin against doxorubicin-induced myocardial toxicity in rats; emphasis on modulation of inflammatory-apoptotic signaling [Pubmed: 33199237] |
| ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY | Chemo-preventive effect of crocin against experimentally-induced hepatocarcinogenesis via regulation of apoptotic and Nrf2 signaling pathways [Pubmed: 32942000] |
| J Biochem Mol Toxicol | Tranilast abrogates cisplatin?\induced testicular and epididymal injuries: An insight into its modulatory impact on apoptosis/proliferation [34047436] |
留言咨詢
